-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Imago BioSciences (NASDAQ:IMGO) Trading 8.3% Higher
Imago BioSciences (NASDAQ:IMGO) Trading 8.3% Higher
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating)'s stock price traded up 8.3% during mid-day trading on Thursday . The company traded as high as $16.12 and last traded at $16.12. 1 shares traded hands during trading, a decline of 100% from the average session volume of 108,936 shares. The stock had previously closed at $14.88.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reduced their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Price Performance
The business's 50-day moving average price is $16.25 and its two-hundred day moving average price is $17.12. The company has a market capitalization of $540.18 million, a price-to-earnings ratio of -9.24 and a beta of 2.48.
Insider Activity
In other news, insider Jennifer Peppe sold 5,598 shares of Imago BioSciences stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.41, for a total value of $108,657.18. Following the completion of the sale, the insider now directly owns 148,809 shares in the company, valued at $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 8,168 shares of company stock worth $155,402. Corporate insiders own 14.90% of the company's stock.Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY acquired a new position in Imago BioSciences during the first quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock worth $30,000 after buying an additional 809 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Imago BioSciences during the first quarter worth $41,000. Legal & General Group Plc increased its holdings in shares of Imago BioSciences by 46.2% during the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after buying an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the second quarter worth $119,000. 99.50% of the stock is currently owned by institutional investors and hedge funds.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Featured Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- GameStop Stock Just Flashed A Buy Signal
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating)'s stock price traded up 8.3% during mid-day trading on Thursday . The company traded as high as $16.12 and last traded at $16.12. 1 shares traded hands during trading, a decline of 100% from the average session volume of 108,936 shares. The stock had previously closed at $14.88.
纳斯达克交易代码：IMGO-GET周四午盘，Imago BioSciences，Inc.股价上涨8.3%，盘中一度涨至16.12美元，最新报16.12美元。盘中成交量为1美元，较108,936股的平均成交量下跌一倍。此前该股收盘价为14.88美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, HC Wainwright reduced their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, August 16th.
另外，HC Wainwright将Imago BioSciences的目标价从36.00美元下调至35.00美元，并在8月16日(星期二)的一份报告中为该公司设定了“买入”评级。
Imago BioSciences Price Performance
Imago BioSciences性价比
The business's 50-day moving average price is $16.25 and its two-hundred day moving average price is $17.12. The company has a market capitalization of $540.18 million, a price-to-earnings ratio of -9.24 and a beta of 2.48.
该业务的50日移动均线价格为16.25美元，200日移动均线价格为17.12美元。该公司市值为5.4018亿美元，市盈率为-9.24倍，贝塔系数为2.48。
Insider Activity
内幕活动
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY acquired a new position in Imago BioSciences during the first quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock worth $30,000 after buying an additional 809 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Imago BioSciences during the first quarter worth $41,000. Legal & General Group Plc increased its holdings in shares of Imago BioSciences by 46.2% during the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after buying an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the second quarter worth $119,000. 99.50% of the stock is currently owned by institutional investors and hedge funds.
机构投资者最近增持或减持了该公司的股份。纽约大都会人寿保险公司在第一季度收购了Imago BioSciences的一个新头寸，价值约为2.8万美元。今年第一季度，ameritas Investment Partners Inc.增持的Imago BioSciences股票增加了108.3%。Ameritas Investment Partners Inc.现在持有1,556股该公司股票，价值30,000美元，该公司在上个季度又购买了809股。合并银行在第一季度收购了价值4.1万美元的Imago BioSciences股票的新头寸。Legal&General Group Plc在第二季度增持了Imago BioSciences的股票46.2%。Legal&General Group Plc现在持有该公司6,098股股票，价值81,000美元，上个季度又购买了1,926股。最后，瑞士信贷股份公司在第二季度收购了Imago BioSciences价值11.9万美元的新头寸。该公司99.50%的股票目前由机构投资者和对冲基金持有。
About Imago BioSciences
关于Imago BioSciences
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences，Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品，LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat，正在进行第二阶段临床试验，用于治疗骨髓增生性肿瘤和慢性骨髓癌，如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- GameStop Stock Just Flashed A Buy Signal
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 安相能源有足够的动力继续提高动力吗？
- 独一无二的氢燃料电池库存
- 这两只被低估的股票已经做好了进一步冲高的准备
- 化工和化肥库存中是否隐藏着宝藏？
- GameStop股票刚刚闪烁了买入信号
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧